Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a specific share repurchase transaction executed on June 18, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 1,500,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,454.5 pence per share; lowest price paid was 1,429.5 pence per share.
- Treasury Holdings (Settled): 464,107,927 shares (8.49% of total issued share capital).
- Treasury Holdings (Including Unsettled): 468,507,927 shares (9.37% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,001,610,326 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,500,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.37% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (464,107,927 settled vs. 468,507,927 including unsettled).
- Confirm the denominator for voting rights calculations is 5,001,610,326 shares.
- Review the price range paid (1,429.5 to 1,454.5 pence) against market prices on June 18, 2012.
- Note that this filing does not contain operational or financial performance data.